Next Article in Journal
No Longer Underappreciated: The Emerging Concept of Astrocyte Heterogeneity in Neuroscience
Previous Article in Journal
Exposure Therapy for Post-Traumatic Stress Disorder: Factors of Limited Success and Possible Alternative Treatment
Previous Article in Special Issue
Efficacy of Cell-Based Therapies for Traumatic Brain Injuries
Open AccessArticle

Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease

1
Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123 Catania, Italy
2
University Sapienza, Piazzale A. Moro, 5, 00185 Roma, Italy
3
IRCCS Neuromed, Località Camerelle, 86077 Pozzilli (IS), Italy
4
Department of Educational Sciences, University of Catania, 95100 Catania, Italy
5
Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Block 23, 1113 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Brain Sci. 2020, 10(3), 166; https://doi.org/10.3390/brainsci10030166
Received: 6 February 2020 / Revised: 28 February 2020 / Accepted: 11 March 2020 / Published: 13 March 2020
(This article belongs to the Special Issue Stem Cell Therapy in Neurodegenerative Diseases)
Alzheimer’s disease (AD) represents the most common neurodegenerative disorder, with 47 million affected people worldwide. Current treatment strategies are aimed at reducing the symptoms and do slow down the progression of the disease, but inevitably fail in the long-term. Induced pluripotent stem cells (iPSCs)-derived neuronal cells from AD patients have proven to be a reliable model for AD pathogenesis. Here, we have conducted an in silico analysis aimed at identifying pathogenic gene-expression profiles and novel drug candidates. The GSE117589 microarray dataset was used for the identification of Differentially Expressed Genes (DEGs) between iPSC-derived neuronal progenitor (NP) cells and neurons from AD patients and healthy donors. The Discriminant Analysis Module (DAM) algorithm was used for the identification of biomarkers of disease. Drugs with anti-signature gene perturbation profiles were identified using the L1000FWD software. DAM analysis was used to identify a list of potential biomarkers among the DEGs, able to discriminate AD patients from healthy people. Finally, anti-signature perturbation analysis identified potential anti-AD drugs. This study set the basis for the investigation of potential novel pharmacological strategies for AD. Furthermore, a subset of genes for the early diagnosis of AD is proposed. View Full-Text
Keywords: Alzheimer disease; Induced pluripotent stem cells-derived neuronal cells; drug repurposing; biomarkers Alzheimer disease; Induced pluripotent stem cells-derived neuronal cells; drug repurposing; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Cavalli, E.; Battaglia, G.; Basile, M.S.; Bruno, V.; Petralia, M.C.; Lombardo, S.D.; Pennisi, M.; Kalfin, R.; Tancheva, L.; Fagone, P.; Nicoletti, F.; Mangano, K. Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. Brain Sci. 2020, 10, 166.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop